10x Genomics Executive Compensation Details Revealed
Ticker: TXG · Form: DEF 14A · Filed: Apr 14, 2025 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | DEF 14A |
| Filed Date | Apr 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: TXG
TL;DR
10x Genomics DEF 14A shows exec comp details for 2024, including equity awards.
AI Summary
10x Genomics, Inc. filed its DEF 14A on April 14, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its principal executive officers (PEO) and non-principal executive officers (Non-PEO/NEO). Specific details on the fair value of these awards, changes in fair value, and vesting dates are provided for the applicable fiscal year.
Why It Matters
This filing provides transparency into how 10x Genomics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can sometimes reveal information that impacts stock price or investor confidence.
Key Players & Entities
- 10x Genomics, Inc. (company) — Filer of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- 20250414 (date) — Filing date of the DEF 14A
FAQ
What is the total reported compensation for the Named Executive Officers (NEOs) for the fiscal year ended December 31, 2024?
The filing does not explicitly state a single total compensation figure for all NEOs in the provided text snippet. It details components like equity awards and their fair values.
What was the fair value of equity awards granted to PEO members in 2024?
The filing indicates data points related to the fair value of equity awards granted to PEO members for the year 2024, but the specific dollar amount is not present in this excerpt.
When was the DEF 14A filing submitted to the SEC?
The DEF 14A filing was submitted on April 14, 2025 (20250414).
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing is a proxy statement filed by a company to solicit shareholder votes, often including details on executive compensation, director nominations, and other corporate governance matters.
Does the filing specify the number of shares or options granted as equity awards?
The provided text snippet focuses on the fair value and changes in fair value of equity awards, not the specific number of shares or options granted.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 regarding 10x Genomics, Inc. (TXG).